Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.
Saved in:
| Title: | Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. |
|---|---|
| Authors: | Bopp AR; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Lamenza FF; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Upadhaya P; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Ryan NM; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Kazmierowicz N; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Jordanides PP; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Siddiqui A; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Pracha SH; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Roth P; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Iwenofu OH; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA., Oghumu S; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA. oghumu.1@osu.edu. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 30; Vol. 74 (7), pp. 227. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04081-5 |
